| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | March 13, 2025 4:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/2/2025 | $12.00 | Buy | TD Cowen |
4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
Submission Seeks Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Comprehensive Data Package Includes Positive Results from Phase 3 STRIVE-ON Safety Trial of GTx-104 Submission Has the Potential to Trigger Exercise of up to $7.6 million in Gross Proceeds from 2023 Financing Warrants Tied to FDA Acceptance of NDA for Review PRINCETON, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in ane
Held Type C meeting with FDA on Planned New Drug Application (NDA) Submission, Including Clinical, Non-clinical, and Chemistry, Manufacturing, and Control (CMC) Requirements NDA On Track for Submission to FDA in First Half of Calendar 2025 NDA to be Supported by Data from Phase 3 STRIVE-ON Safety Trial, which Met Primary Endpoint and Provided Evidence of Clinical Benefit Compared to Orally Administered Nimodipine Secured Private Placement Financing of $15 Million in Upfront Gross Proceeds with the Potential to Receive up to an Additional $15 Million in Potential Warrant Exercise Proceeds for an Aggregate of Up to Approximately $30 Million in Potential Total Gross Proceeds PRINCETON, N.J.
PRINCETON, N.J., June 13, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that Chief Executive Officer Prashant Kohli will participate in the upcoming BIO 2025 International Conference, to be held in Boston, MA, June 16-19, 2025. Hosted by the Biotechnology Innovation Organization (BIO), the BIO International Convention is the world's largest and most influential biotechnology event
TD Cowen initiated coverage of Grace Therapeutics with a rating of Buy and set a new price target of $12.00
8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
10-K - Grace Therapeutics, Inc. (0001444192) (Filer)
BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025 (the "Effective Date"). In addition, Matthew Wikler, M.D., and Natasha Giordano stepped down from the Board on the Effective Date. "We are thrilled to announce the addition of Keith and Edward to our Board," stated Jerome D. Jabbour, Chief Executive Officer of Matinas. "Their deep industry experience, leadership expertise, and capital markets acumen will be of great value as we move the company forward into a new era continu
SC 13G/A - Grace Therapeutics, Inc. (0001444192) (Subject)
SC 13G/A - Grace Therapeutics, Inc. (0001444192) (Subject)